Aspirin Derivatives Exploration: A Review on Comparison Study with Parent Drug

Authors

  • Azni Izwati Hamdan University of Sultan Zainal Abidin
  • Norsyafikah Asyilla Nordin University of Sultan Zainal Abidin
  • Dike Dandari Sukmana University of Sultan Zainal Abidin

DOI:

https://doi.org/10.31351/vol31iss2pp14-32

Keywords:

Aspirin, Aspirin Derivatives, Biological Activities, Chemical Modification, NSAIDs

Abstract

In recent decades, drug modification is no longer unusual in the pharmaceutical world as living things are evolving in response to environmental changes. A non-steroidal anti-inflammatory drug (NSAID) such as aspirin is a common over-the-counter drug that can be purchased without medical prescription. Aspirin can inhibit the synthesis of prostaglandin by blocking the cyclooxygenase (COX) which contributes to its properties such as anti-inflammatory, antipyretic, antiplatelet and etc. It is also being considered as a chemopreventive agent due to its antithrombotic actions through the COX’s inhibition. However, the prolonged use of aspirin can cause heartburn, ulceration, and gastro-toxicity in children and adults. This review article highlights the recent derivatives of aspirin, either to reduce the risk of side effects or to obtain better physicochemical properties. Aspirin derivatives can be synthesized in various pathways and have been reported to give better biological activities such as anticancer, anti-inflammatory, antibacterial, antioxidant, etc., compared to the parent drug. The presence of significant moieties such as nitric oxide (NO), NOSH, thiourea, azo, amide, and chalcone on the modified aspirin play important roles in achieving desired biological activities. The addition of the halogen in the modification has also become a preference among researchers as it also affects the actions due to its ability to hinder bacterial activity. This review is also sharing about the bulkiness effect of certain aspirin modifications that may cause steric hindrance of the compounds and influence their penetration into the enzyme’s active site. Overall, these aspirin modifications are safe to be considered as potential pharmaceutical agents.

References

Santos-Gallego CG, Badimon J. Overview of Aspirin and Platelet Biology. Am J Cardiol . 2021 Apr;144:S2–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S000291492031345X

Lourenço AL, Saito MS, Dorneles LEG, Viana GM, Sathler PC, De Aguiar LCS, et al. Synthesis and antiplatelet activity of antithrombotic thiourea compounds: Biological and structure-activity relationship studies. Molecules. 2015;20(4):7174–200.

Ittaman S V., VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014;12(3–4):147–54.

Hankey GJ, Eikelboom JW. Antiplatelet drugs. Med J Aust . 2003 Jun 2;178(11):568–74. Available from: https:// onlinelibrary .wiley.com/doi/abs/10.5694/j.1326-5377. 2003.tb05361.x

Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011;124(5):426–33.

Jiang S, Zhang L, Cui D, Yao Z, Gao B, Lin J, et al. The Important Role of Halogen Bond in Substrate Selectivity of Enzymatic Catalysis. Sci Rep. 2016;6(September):1–7.

Saccone M, Catalano L. Halogen Bonding beyond Crystals in Materials Science. J Phys Chem B . 2019 Nov 7;123(44):9281–90. Available from: https://pubs.acs.org/doi/10.1021/acs.jpcb.9b07035

Fiala C, Pasic MD. Aspirin: Bitter pill or miracle drug? Clin Biochem . 2020 Nov 1 [cited 2021 Mar 25];85:1–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S000991202030792X

Thota PNPN. Aspirin: the miracle drug? Clin Transl Gastroenterol . 2018;9(153):4–5. Available from: http://dx.doi. org/10 .1038/ s41424-018-0009-4

Song JM, Upadhyaya P, Kassie F. Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway. Carcinogenesis. 2018;39(7):911–20.

Downloads

Published

2022-12-23